TSUMURA & CO. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,966 JPY | -2.24% |
|
+5.71% | +49.22% |
ETFs positioned on Tsumura & Co.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.53% | 19 M€ | +11.51% | ||
| 0.04% | 17 M€ | +15.04% | - | |
| 0.03% | 20,360 M€ | +15.69% | - | |
| 0.03% | 63,295 M€ | +16.80% | - | |
| 0.03% | 140,441 M€ | +16.75% | ||
| 0.01% | 746 M€ | -.--% | - | |
| 0.01% | 32 M€ | +0.82% | - | |
| 0.01% | 7 M€ | +5.65% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.01% | 32 M€ | +8.03% | - | |
| 0.00% | 45 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +8.28% | - | |
| 0.00% | 391 M€ | +8.36% | - | |
| 0.00% | 39 M€ | +5.31% | - | |
| 0.00% | 306 M€ | +5.71% | - | |
| 0.00% | 34 M€ | +3.53% | - |
TSUMURA & CO. is a Japan-based company mainly engaged in the manufacture and sale of ethical and general pharmaceuticals. Through its subsidiaries, the Company is also engaged in the procurement, sorting and processing of crude drugs, the manufacture and sale of Chinese herbal extract powders and drug substances, the operation of dispensing pharmacies and the provision of logistics services, as well as the development of pharmaceuticals.
Sector
Pharmaceuticals
Calendar
2024-11-05
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4,057
JPY
Average target price
4,920
JPY
Spread / Average Target
+21.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +49.22% | 1.97B | |
| +31.06% | 688B | |
| +30.35% | 588B | |
| -3.42% | 364B | |
| +18.02% | 326B | |
| +4.27% | 285B | |
| +15.53% | 239B | |
| +10.16% | 210B | |
| -8.14% | 200B | |
| +8.12% | 167B |
- Stock Market
- Equities
- 4540 Stock
- Funds and ETFs Tsumura & Co.